Janardhan Keshav Karapurkar , Ph.D

Post-Doc                                                                                                                                                     

Email: kalpesh25021992@gmail.com

Research Interest: Cancer biology, Genome Editing, Hybridoma technology, In vivo studies, Immunology, Stem cell technology

Chapter

1. CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals. Karapurkar JK*, Antao AM*, Kim KS  and Ramakrishna S *. Progress in Molecular Biology and Translational Science (IF: 4.07). 2021, In Press. (*Equal co-first authors).

Research Publications

13. E3 Ubiquitin ligase APC/Cdh1 regulates SLC35F2 protein turnover and inhibits cancer progression in HeLa cells. Colaco JC, Chandrasekaran AP, Karapurkar JK, Gowda ADA, Birappa G, Rajkumar S, Suresh B, Ko N, Hong SH, Oh SJ, Kim KS, Ramakrishna S. BBA-General Subjects. 2023, In Press.   

12. CRISPR/Cas9-based genome-wide screening of the deubiquitinase subfamily identifies USP3 as a protein stabilizer of REST blocking neuronal differentiation and promotes neuroblastoma tumorigenesis. Karapurkar JK, Kim MS, Colaco JC, Suresh B, Sarodaya N, Kim DH, Park CH, Hong SH, Kim KS, Ramakrishna S. Journal of Experimental Clinic and Cancer Research. 2023 42: 121. (IF: 12.65). (Co-First author).

11. USP19 negatively regulates p53 and promotes cervical cancer progression. Tyagi A, Karapurkar JK, Colaco JC, Sarodaya N, Antao AM, Kaushal K, Haq S, Chandrasekaran AP, Das S, Singh V, Singh V, Hong SH, Suresh B*, Kim KS*, Suresh Ramakrishna*. *(Co-First author). Molecular biotechnology. In Press

10. Phage Engineering and phage-assisted CRISPR-Cas delivery to combat mutidrug-resistant pathoges. Khambhati K, Bhattacharjee G, Gohil N, Dhanoa GK, Sagona AP, Mani I, Bui NL, Chu DT, Karapurkar JK, Jang SH, Chung HY, Maurya R, Alzahrani KJ, Ramakrishna S, Singh V. Bioengineering and Translational Medicine. (IF: 10.6), 2022. 8: e13381.

9. Dual role of deubiquitinating enzyme USP19 regulates mitotic progression and tumorigenesis by stabilizing survivin. Chandrasekaran AP, Tyagi A, Poondla N, Sarodaya N, Karapurkar JK, Kaushal K, Park CH, Hong SH, Kim KS*, Ramakrishna S*. Molecular Therapy (IF: 11.45). 2022, 30: 3414-3429. 

8. Genome-wide screening for deubiquitinase subfamily identifies ubiquitin-specific protease 49 as a novel regulator of odontogenesis. Kaushal K, Kim EJ, Tyagi A, Karapurkar JK, Haq S, Jung HS*, Kim KS*, Ramakrishna S*. Cell Death and Differentiation (IF: 15.8). 2022, 29: 1689-1704. 

7. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Bhattacharjee G, Gohil N, Khambhati K, Mani I, Maurya R, Karapurkar JK, Gohil J, Chu DT, Vu-Thi H, Alzahrani KJ, Show PL, Rawal RM, Ramakrishna S*, Singh V*. Journal of Controlled Release, (IF: 11.47), 2022, 343:703-723. 

6. The role of the CRISPR-Cas system in cancer drug development: Mechanisms of action and therapy. Chandrasekaran AP*, Karapurkar JK*, Chung HY, Ramakrishna S. Biotechnology Journal (IF: 4.67). 2022,17(7): e2100468. (Co-First author).  

5. Genome-wide CRISPR/Cas9-based screening for Deubiquitinase subfamily identifies ubiquitin-specific protease 11 as a novel regulator of osteogenic differentiation. Kaushal K, Tyagi A, Karapurkar JK, Kim EJ, Tanguturi P, Kim KS*, Jung HS*, Ramakrishna S*. International Journal of Molecular Science (IF: 6.02). 2022. 23(2): 856. 

4. CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression. Haq S, Sarodaya N, Karapurkar JK, Suresh B, Jo JK, Singh V, Bae YS, *Kim KS and *Ramakrishna S. Cancer Letters (IF: 8.67), 2022, 525: 146-157.  

3. Ubiquitin-specific Protease 3 deubiquitinates and stabilizes Oct4 protein in human embryonic stem cells. Rhie BH, Antao AM, Karapurkar JK, Kim MS, Jo WJ, Ramakrishna S and Kim KS. International journal of Molecular Science (IF: 4.5). 2021, 22: 5584. (Co-authors). 

2. Disease modeling and stem cell immunoengineering in regenerative medicine using CRISPR/Cas9 systems. Antao AM*, Karapurkar JK*, Lee DR, Kim KS, Ramakrishna S. Computational and Structural Biotechnology Journal. (IF: 6.01) 2020, 18:3649-3665. (*Equal co-first authors). 

1. The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies. Sarodaya N*, Karapurkar J*, Kim KS, Hong SH, Ramakrishna S. Cancers (Basel). 2020;12(5):E1103. (*Equal co-first authors).Po